Can-Fite BioPharma faces a precarious outlook as its reliance on sporadic licensing milestones fails to offset a consistent quarterly cash burn of $2.4 million. The company's fundamental value proposition remains tied to clinical pipeline progression, yet the ...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 8, 2026 | -$0.33+0.0% vs -$0.33 | — vs $300,000 |
Q2 2026 Mar 26, 2026 | -$5.97+77.9% vs -$27.00 | $203,000-32.3% vs $300,000 |
Q3 2025 Aug 28, 2025 | -$0.00+100.0% vs -$4.15 | $202,000-59.6% vs $500,000 |
Q2 2025 Apr 14, 2025 | -$0.10+0.0% vs -$0.10 | $101,000-79.8% vs $500,000 |
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise price of $5.00 per ADS, issued by Can-Fite in March 2026, at a reduced exercise price of $2.50 per ADS. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-3 (File No. 333-294760). The closing of the offering is expected to occur on or about September 3, 2026, subject to satisfaction of customary closing conditions.
Benchmark CANF against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Can-Fite BioPharma Ltd. (CANF)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.81 | $1.55M | -0.15 | -39.43% | -2426.67% | -179.65% | — | |
| $18.54 | $2.33B | -5.64 | -4.26% | -386.32% | -87.98% | — | |
| $252.96 | $7.05B | -18.77 | -100% | — | -34.15% | — | |
| $19.73 | $3.38B | 8.62 | 11.87% | 33.42% | 32.39% | — | |
| $20.66 | $1.52B | 6.26 | 18.52% | 80.56% | 30.03% | — | |
| $285.64 | $504.67B | 120.52 | 8.57% | 9.81% | — | — |
Can-Fite BioPharma Ltd. (CANF) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CANF posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Can-Fite BioPharma Ltd. (CANF) stock FAQ — growth, dividends, profitability & financials explained
Can-Fite BioPharma Ltd. (CANF) reported $0.4M in revenue for fiscal year 2025. This represents a 14% decrease from $0.5M in 2011.
Can-Fite BioPharma Ltd. (CANF) saw revenue decline by 39.4% over the past year.
Can-Fite BioPharma Ltd. (CANF) reported a net loss of $9.6M for fiscal year 2025.
Can-Fite BioPharma Ltd. (CANF) has a return on equity (ROE) of -179.7%. Negative ROE indicates the company is unprofitable.
Can-Fite BioPharma Ltd. (CANF) had negative free cash flow of $9.5M in fiscal year 2025, likely due to heavy capital investments.
